Asia Pacific Exosome Therapeutics Market – Industry Trends and Forecast to 2029

Market Analysis and Insights: Asia Pacific Exosome Therapeutics Market

 Asia Pacific exosome therapeutics market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.4% in the forecast period of 2022 to 2029 and is expected to reach USD 404.38 thousand by 2029 from USD 122.59 thousand in 2021. The rising prevalence of chronic inflammatory autoimmune diseases and technological developments in exosome therapeutics are likely to act as the major drivers for the demand of the market in the forecast period.

The exosomes are a specific class of cell-derived extracellular vesicles composed of endosomes and are typically 30-150 nm in diameter – the smallest type of extracellular vesicle. Protected by a lipid bilayer, the exosomes are pushed into the extracellular environment, which contains a complex cargo of contents derived from the original cell. The contents present in the cargo are proteins, lipids, messenger ribonucleic acid (mRNA), microsomal ribonucleic acid (miRNA), and deoxyribonucleic acid (DNA). The exosomes are distinct by how they are formed – through the fusion and exocytosis of multivesicular bodies into the extracellular space. The exosomes have been connected to treat various chronic conditions such as autoimmune disorders. Nanotechnology has shown novel insights for the prior detection of cancer-based on nanocarriers such as exosomes. Since the exosomes provide strong potential for applicability in therapeutic interventions, the exosomes have been regarded as potential drug carriers.

The exosomes consist of two types, the natural exosomes, and the hybrid exosomes. The natural exosomes are further sub-segmented into exogenous exosomes and autologous exosomes. The autologous exosomes are safe and operative vehicles for the targeted delivery of drugs for the treatment of cancer, autoimmune diseases, and chronic inflammatory diseases. The exogenous exosomes are tiny extracellular membrane vesicles released from endosomes of various cells and can be found in most of the body fluids, such as the synovial fluid, amniotic fluid, and semen. In cancer, exosomes have vital roles in the metastatic spread, drug resistance, and the formation of new blood vessels.

The driving factors responsible for the growth of the Asia-Pacific exosome therapeutics market are the increased incidence of chronic inflammatory diseases, the rise in research and development activities for exosome therapeutics, and government funding for the development and production of exosome therapeutics. Moreover, the growth potential in the emerging economies for exosome therapeutics and increased use of anti-aging therapy bolsters the exosome therapeutics market growth. However, the rise in cost, the stringent regulations imposed, and the risks observed while using the exosome therapeutics are the restraints that may hinder the market growth. An increase in healthcare expenditure is expected to provide a lucrative opportunity for market growth. On the other hand, rising investments, coupled with a lack of standardized procedures for isolating exosomes as well as non-availability of required expertise, are some of the significant challenges that are expected to affect the market growth.

The Asia-Pacific exosome therapeutics market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Asia- Pacific Exosome Therapeutics Market Scope and Market Size

Asia-Pacific exosome therapeutics market is categorized into seven notable segments which are based on type, source, therapy, transporting capacity, application, route of administration, and end user.

• On the basis of type, the Asia-Pacific exosome therapeutics market is segmented into natural exosomes and hybrid exosomes. In 2022, the natural exosomes segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the presence of natural material of the exosomes and the benefits in drug delivery.
• On the basis of source, the Asia-Pacific exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva, milk, and others. In 2022, the mesenchymal stem cell segment is expected to dominate the Asia-Pacific exosome therapeutics market due to emerging applications of mesenchymal stem cells and expansion of pipeline, availability, and ease of harvesting.
• On the basis of therapy, the Asia-Pacific exosome therapeutics market is segmented into immunotherapy, gene therapy, and chemotherapy. In 2022, the immunotherapy segment is expected to dominate the Asia-Pacific exosome therapeutics market due to ease of convenience, high accuracy, and improvement in the long-term survival rate.
• On the basis of transporting capacity, the Asia-Pacific exosome therapeutics market is segmented into bio macromolecules and small molecules. In 2022, the bio macromolecules segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the presence of high sensitivity, increased use of protein therapeutics to cure inflammatory disorders, and boosting the natural defenses in the body to combat inflammatory diseases.
• On the basis of application, the Asia-Pacific exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders, and others. In 2022, the metabolic disorders segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the increase in cases of metabolic disorders in China and India and the availability of exosome therapeutics in diagnostic laboratories.
• On the basis of route of administration, the Asia-Pacific exosome therapeutics market is segmented into parenteral and oral. In 2022, the parenteral segment is expected to dominate the Asia-Pacific exosome therapeutics market due to enhanced bioavailability and immediate onset of action.
• On the basis of end user, the Asia-Pacific exosome therapeutics market is segmented into research and academic institutes, hospitals, and diagnostics centers. In 2022, the research and academic institutes segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the rise in research and development of exosomes in Japan and support from the government in funding.

Asia-Pacific Exosome Therapeutics Market Country Level Analysis

Asia-Pacific exosome therapeutics market is analyzed, and market size information is provided by type, source, therapy, transporting capacity, application, route of administration, and end user.

The countries covered in the exosome therapeutics market report are Japan, China, India, South Korea, Australia, Singapore, Indonesia, the Philippines, and rest of Asia-Pacific.

Asia-Pacific is expected to grow with the highest CAGR in the forecast periods as in the Asia-Pacific's countries demand exosome therapeutics products is increasing very rapidly with the urbanization and laboratory automation. China is expected to dominate in the market in the Asia-Pacific market as China is one of the leading countries to inculcate the exosome therapeutics market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential For Exosome Therapeutics In Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The Asia-Pacific Exosome Therapeutics Market 

 Asia Pacific exosome therapeutics market also provides you with detailed market analysis for every country's growth in a particular industry with exosome therapeutics sales, the impact of advancement in the exosome therapeutics, and changes in regulatory scenarios with their support for the exosome therapeutics market. The data is available for the historic period 2011 to 2020.

Competitive Landscape and Asia Pacific Exosome Therapeutics Market Share Analysis

 Asia Pacific exosome therapeutics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the exosome therapeutics market.

The major company providing Asia- Pacific exosome therapeutics is Exopharm.

DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players along with new technological advancements for exosome therapeutics are bridging the gap for the treatment of chronic autoimmune diseases.

For instance,

• In September 2021, Exopharm collaborated with Japan's Showa Denko Materials for the use of LEAP technology in exosome therapeutics. The LEAP technology reduces the major problem faced during the production of exosome s, which are used as regenerative medicine for diseases such as cancer. The collaboration would evaluate Exopharm's LEAP – Ligand-based Exosome Affinity Purification – technology platform within its Yokohama regenerative medicine business unit. It would result in Showa Denko Materials leveraging the exosome technology of Exopharm

Collaboration, joint ventures, and other strategies by the market players are enhancing the company market in the exosome therapeutics market, which also provides the benefit for the organization to improve their offering for the exosome therapeutics market.

SKU-50630